Stryker (SYK) 10-Q 23 Oct 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2015shares
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	SYK
Entity Registrant Name	STRYKER CORP
Entity Central Index Key	310,764
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	375,522,232

Consolidated Statements Of Earn

Consolidated Statements Of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net sales	$ 2,420	$ 2,389	$ 7,231	$ 7,057
Cost of sales	796	829	2,449	2,420
Gross profit	1,624	1,560	4,782	4,637
Research, development and engineering expenses	155	153	461	461
Selling, general and administrative expenses	887	878	2,640	2,607
Recall charges	150	29	316	649
Intangible asset amortization	54	50	152	142
Total operating expenses	1,246	1,110	3,569	3,859
Operating income	378	450	1,213	778
Other income (expense), net	(33)	(25)	(90)	(79)
Earnings before income taxes	345	425	1,123	699
Income taxes	44	368	206	444
Net earnings	$ 301	$ 57	$ 917	$ 255
Net earnings per share of common stock:
Basic net earnings per share of common stock	$ 0.80	$ 0.16	$ 2.43	$ 0.68
Diluted net earnings per share of common stock	$ 0.79	$ 0.16	$ 2.40	$ 0.67
Weighted-average shares outstanding - in millions:
Basic	376.3	378.4	377.4	378.5
Net effect of dilutive employee stock options	4.4	4.1	4.4	4.2
Diluted	380.7	382.5	381.8	382.7
Anti-dilutive shares excluded from the calculation of net effect of dilutive employee stock options	0	0	0	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net earnings	$ 301	$ 57	$ 917	$ 255
Other comprehensive income (loss), net of tax
Marketable securities	0	(3)	(3)	4
Pension plans	0	5	10	5
Unrealized gains (losses) on designated hedges	(15)	5	(4)	(7)
Financial statement translation	(83)	(312)	(278)	(308)
Total other comprehensive loss, net of tax	(98)	(305)	(275)	(306)
Comprehensive income (loss)	$ 203	$ (248)	$ 642	$ (51)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 3,163	$ 1,795
Marketable securities	209	3,205
Accounts receivable, less allowance of $68 ($59 in 2014)	1,496	1,572
Inventories
Materials and supplies	296	248
Work in Process	113	88
Finished Goods	1,256	1,252
Total inventories	1,665	1,588
Deferred income taxes	933	989
Prepaid expenses and other current assets	567	524
Total current assets	8,033	9,673
Property, plant and equipment
Land, buildings and improvements	680	678
Machinery and equipment	1,976	1,919
Total property, plant and equipment	2,656	2,597
Less allowance for depreciation	1,528	1,499
Net property, plant and equipment	1,128	1,098
Other assets
Goodwill	4,160	4,186
Other intangibles, net	1,861	2,018
Other	735	738
Total assets	15,917	17,713
Current liabilities
Accounts payable	340	329
Accrued compensation	532	597
Income taxes	158	333
Dividend payable	130	131
Accrued recall expenses	697	1,593
Accrued expenses and other liabilities	725	754
Current maturities of debt	971	727
Total current liabilities	3,553	4,464
Long-term debt, excluding current maturities	2,511	3,246
Other liabilities	1,369	1,408
Shareholders' equity
Common stock, $0.10 par value: Authorized: 1 billion shares, outstanding: 378 million shares (378 million in 2014)	38	38
Additional paid-in capital	1,319	1,252
Retained earnings	7,656	7,559
Accumulated other comprehensive income	(529)	(254)
Total shareholders' equity	8,484	8,595
Total liabilities & shareholders' equity	$ 15,917	$ 17,713

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 68	$ 59
Common stock, par value (in dollars per share)	$ 0.1	$ 0.1
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, outstanding (in shares)	376,000,000	378,000,000

Consolidated Statement Of Share

Consolidated Statement Of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2015 - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Balances at December 31, 2014 at Dec. 31, 2014	$ 8,595	$ 38	$ 1,252	$ 7,559	$ (254)
Net earnings	917			917
Other comprehensive loss	(275)				(275)
Issuance of 1.6 million shares of common stock under stock option and benefit plans, including $23 excess income tax benefit	18		18
Repurchase and retirement of 4.7 million shares of common stock	(446)		(16)	(430)
Share-based compensation	65		65
Cash dividends declared of $1.035 per share of common stock	(390)			(390)
Balances at September 30, 2015 at Sep. 30, 2015	$ 8,484	$ 38	$ 1,319	$ 7,656	$ (529)

Consolidated Statement Of Shar7

Consolidated Statement Of Shareholders' Equity (Unaudited) (Parenthetical) shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Statement of Stockholders' Equity [Abstract]
Issuance of common stock under stock option and benefit plans, shares	1.6
Issuance of common stock under stock option and benefit plans, excess income tax benefit | $	$ 23
Repurchase and retirement of common stock, shares	4.7
Cash dividends declared, per share of common stock | $ / shares	$ 1.035

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net earnings	$ 917	$ 255
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	137	140
Amortization of intangible assets	152	142
Share-based compensation	65	58
Gross recall charges	316	649
Sale of inventory stepped up to fair value at acquisition	7	24
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable	26	(12)
Inventories	(124)	(217)
Accounts payable	15	15
Accrued expenses and other liabilities	(35)	113
Recall-related payments	(1,172)	(62)
Income taxes	(241)	169
Other	165	(171)
Net cash provided by operating activities	228	1,103
Investing activities
Acquisitions, net of cash acquired	(140)	(825)
Purchases of marketable securities	(1,184)	(3,635)
Proceeds from sales of marketable securities	4,056	2,842
Purchases of property, plant and equipment	(191)	(172)
Net cash provided by (used in) investing activities	2,541	(1,790)
Financing activities
Proceeds from borrowings	1,298	2,208
Payments on borrowings	(1,799)	(1,013)
Dividends paid	(391)	(346)
Repurchase and retirement of common stock	(446)	(100)
Other financing	36	(38)
Net cash (used in) provided by financing activities	(1,302)	711
Effect of exchange rate changes on cash and cash equivalents	(99)	(7)
Change in cash and cash equivalents	1,368	17
Cash and cash equivalents at beginning of year	1,795	1,339
Cash and cash equivalents at end of year	$ 3,163	$ 1,356

Basis Of Presentation

Basis Of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION General Information These statements should be read in conjunction with our Annual Report on Form 10-K for 2014 . Management believes that the accompanying unaudited Consolidated Financial Statements include all adjustments, including normal recurring items, considered necessary for a fair presentation of the interim periods. However, the results of operations included in such financial statements may not necessarily be indicative of annual results. To conform with the current year presentation, certain immaterial amounts previously reported as selling, general and administrative expenses have been reclassified to cost of sales. In addition, certain prior year amounts have been reclassified to conform to the current year presentation of our segment information in Note 10. New Accounting Pronouncements Not Yet Adopted In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This guidance outlines a single, comprehensive model for accounting for revenue from contracts with customers. We will adopt the standard on January 1, 2018. We are still evaluating the impact, if any, that the standard will have on our financial statements. In April 2015 the FASB issued ASU 2015-03, Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. This update requires an entity to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability consistent with debt discounts and is effective for financial statements issued for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. We plan to adopt this standard on January 1, 2016 and do not expect it to have a material impact on the Consolidated Financial Statements. No other new accounting pronouncements issued or effective during the period had, or are expected to have, a material impact on the Consolidated Financial Statements.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 Quoted market prices in active markets for identical assets or liabilities. Level 2 Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3 Unobservable inputs reflecting our assumptions or external inputs from active markets. When applying fair value principles in the valuation of assets and liabilities, we are required to maximize the use of quoted market prices and minimize the use of unobservable inputs. We calculate the fair value of our Level 1 and Level 2 instruments based on the exchange traded price of similar or identical instruments, where available, or based on other observable inputs taking into account our credit risk and that of our counterparties. Foreign currency exchange contracts and interest rate hedges are included in Level 2 as we use inputs other than quoted prices that are observable for the asset or liability. The Level 2 derivative instruments are primarily valued using standard calculations and models that use readily observable market data as their basis. Our Level 3 liabilities represent milestone payments for acquisitions and the fair value is calculated based on the net present value of expected cash flows utilizing a discounted cash flow technique based on externally provided or obtained inputs, including our probability assessments of the occurrence of triggering events, appropriately discounted considering the uncertainties associated with the obligation. There were no significant transfers into or out of any level between December 31, 2014 and September 30, 2015 . We remeasure our assets and liabilities each reporting period and record the changes in fair value from changes in probability of occurrence in selling, general and administrative expense and the changes in time value of money in other income (expense). During the period we evaluated but did not change our unobservable input assumptions and fair value techniques used in measuring the fair value of our financial assets or liabilities from those disclosed in our Annual Report on Form 10-K for 2014 . Our valuation of our assets and liabilities measured at fair value is: September December 2015 2014 Cash and cash equivalents $ 3,163 $ 1,795 Trading marketable securities 77 80 Level 1 - Assets $ 3,240 $ 1,875 Available-for-sale marketable securities Corporate and asset-backed debt securities 68 1,525 Foreign government debt securities 80 726 United States agency debt securities 24 382 United States treasury debt securities 34 474 Certificates of deposit 5 110 Other — 12 Total available-for-sale marketable securities 211 3,229 Foreign currency exchange forward contracts 34 32 Interest rate swap asset 23 10 Level 2 - Assets 268 3,271 Total assets measured at fair value $ 3,508 $ 5,146 Deferred compensation arrangements 77 80 Level 1 - Liabilities 77 80 Foreign currency exchange forward contracts 13 12 Interest rate swap liability 8 — Level 2 - Liabilities 21 12 Contingent consideration Beginning Balance 48 59 Additions 9 — Losses included in earnings — 4 Settlements (4 ) (15 ) Balance at the end of the period 53 48 Level 3 - Liabilities 53 48 Total liabilities measured at fair value $ 151 $ 140 The cost and estimated fair value of available-for-sale marketable securities at September 30, 2015 by contractual maturity are: Cost Estimated Due in one year or less $ 90 $ 90 Due after one year through three years 118 118 Due after three years 3 3 Less than 1% of our investments in available-for-sale securities had a credit quality rating of less than A2 (Moody's), A (Standard & Poors) and A (Fitch). We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity; accordingly, we do not consider investments with cost in excess of fair value to be other-than-temporarily impaired at September 30, 2015 . Upon the sale of a security classified as available-for-sale, the security’s specific unrealized gain (loss) is reclassified out of accumulated other comprehensive income (AOCI) into earnings based on the specific identification method. In the 2015 nine months we sold a portion of our marketable securities in preparation for recall-related payments and other cash management activity. See Note 5 for more information. The total of interest and marketable securities income was $1 and $10 for the 2015 and 2014 three months, and $12 and $21 for the 2015 and 2014 nine months. The amounts are included in other income (expense). Summary of marketable securities: September December 2015 2014 Available for Sale Securities: Amortized Cost Corporate and asset-backed debt securities $ 68 $ 1,523 Foreign government debt securities 80 725 United States agency debt securities 24 382 United States treasury debt securities 34 474 Certificates of deposit 5 110 Other — 12 Gross Unrealized Gains Corporate and asset-backed debt securities $ — $ 3 Foreign government debt securities — 2 Gross Unrealized Losses Corporate and asset-backed debt securities $ — $ (1 ) Foreign government debt securities — (1 ) Estimated Fair Value Corporate and asset-backed debt securities $ 68 $ 1,525 Foreign government debt securities 80 726 United States agency debt securities 24 382 United States treasury debt securities 34 474 Certificates of deposit 5 110 Other — 12 Total available-for-sale marketable securities $ 211 $ 3,229 Trading marketable securities 77 80 Total marketable securities $ 288 $ 3,309 Reported as: Current assets - marketable securities $ 209 $ 3,205 Current assets - prepaid expenses and other 2 24 Noncurrent assets - other 77 80 At September 30, 2015 the fair value and gross unrealized losses of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, are: Number of Investments Fair Value Unrealized Losses Corporate and asset-backed 25 $ 21 $ — Foreign Government 4 10 — United States Agency 1 5 — United States Debt 1 — — Certificate of deposit 1 1 — Less than 12 months 32 $ 37 $ — Corporate and asset-backed 26 $ 22 $ — Foreign Government 4 10 — United States Agency 1 5 — United States Debt 1 — — Certificate of Deposit 1 1 — Total 33 $ 38 $ —

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	ACCUMULATED OTHER COMPREHENSIVE INCOME Changes in AOCI for the three months: Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ — $ (126 ) $ 24 $ (329 ) $ (431 ) OCI before reclassifications (1 ) (2 ) (14 ) (83 ) (100 ) Tax (benefit) expense on OCI — — 4 — 4 Reclassifications out of AOCI 1 2 (5 ) — (2 ) Net current period OCI — — (15 ) (83 ) (98 ) Ending $ — $ (126 ) $ 9 $ (412 ) $ (529 ) Changes in AOCI for the nine months: Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning 3 (136 ) 13 (134 ) (254 ) OCI before reclassifications 2 8 6 (278 ) (262 ) Tax (benefit) expense on OCI (1 ) (2 ) (2 ) — (5 ) Reclassifications out of AOCI (4 ) 4 (8 ) — (8 ) Net current period OCI (3 ) 10 (4 ) (278 ) (275 ) Ending — (126 ) 9 (412 ) (529 ) Reclassifications out of AOCI for the three and nine months: Three Months Nine Months 2015 2014 2015 2014 Marketable Securities Other (income) expense $ 1 $ (4 ) $ (5 ) $ (7 ) Tax expense (benefit) — 1 1 1 Net of tax 1 (3 ) (4 ) (6 ) Pension Plans Cost of Sales 2 — 6 — Tax expense (benefit) — — (2 ) (1 ) Net of tax 2 — 4 (1 ) Hedges Cost of Sales (7 ) — (12 ) (4 ) Tax expense (benefit) 2 — 4 2 Net of tax (5 ) — (8 ) (2 ) Total, net of tax $ (2 ) $ (3 ) $ (8 ) $ (9 )

Derivative Instruments

Derivative Instruments	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS We use operational and economic hedges as well as foreign currency exchange forward contracts and interest rate derivative instruments to manage the impact of currency exchange on earnings and cash flow. Foreign Exchange Forward Contract Derivatives We have not changed our hedging strategies or objectives from those disclosed in our Annual Report on Form 10-K for 2014. The gross notional, maximum term and gross fair value amounts of foreign exchange forward contract derivatives designated and non-designated as hedging instruments are: Designated Non-Designated Total September 30, 2015 Gross Notional Amount $ 565 $ 2,366 $ 2,931 Maximum term in days 546 Fair Value Other Current Assets $ 26 $ 6 $ 32 Other Noncurrent Assets 2 — 2 Other Current Liabilities (6 ) (6 ) (12 ) Other Noncurrent Liabilities (1 ) — (1 ) $ 21 $ — $ 21 December 31, 2014 Gross Notional Amount $ 357 $ 2,085 $ 2,442 Maximum term in days 546 Fair Value Other Current Assets $ 18 $ 12 $ 30 Other Noncurrent Assets 2 — 2 Other Current Liabilities — (12 ) (12 ) $ 20 $ — $ 20 The net currency exchange rate gains (losses) for both designated and non-designated derivative instruments and the underlying amounts are: Three Months Nine Months Recorded In: 2015 2014 2015 2014 Cost of goods sold $ 7 $ (1 ) $ 12 $ 4 Other income (expense) (5 ) (2 ) (16 ) (11 ) Total $ 2 $ (3 ) $ (4 ) $ (7 ) Pretax gains on derivatives designated as hedges that are expected to be reclassified from AOCI into earnings within the next twelve months are $ 24 . This reclassification is primarily due to the sale of inventory that includes previously hedged purchases. There have been no ineffective portions of derivatives that have resulted in gains or losses in any of the periods presented. Net Investment Hedge In September 2015 we designated certain long-term intercompany loans payable and forward exchange contracts as net investment hedges of our investments in certain international subsidiaries that use the Euro as their functional currency. The effective portion of derivatives designated as net investment hedges are recorded at fair value at each balance sheet date and the change in fair value is recorded as a component of AOCI. At September 30, 2015 the total after-tax amount in AOCI was $ 8 and the notional value, after tax, of our designated net investment hedges was $ 754 . For the long-term intercompany loan payable designated as net investment hedges, we used the spot method to measure the ineffectiveness. For the forward exchange contracts designated as net investment hedges, we used the forward method to measure ineffectiveness. Under these methods, for each reporting period, the change in the carrying value of the Euro-denominated amounts due to remeasurement of the effective portion is reported as a component of AOCI and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income (expense), net. We evaluate the effectiveness of our net investment hedges quarterly and did not record any ineffectiveness for the 2015 three months. Interest Rate Risk on Future Debt Issuance Forward starting interest rate derivative instruments designated as cash flow hedges are used to manage the exposure to interest rate volatility with regard to future issuance and refinancing of debt. The effective portion of the gains or losses on the forward starting interest rate derivative instruments that are designated and qualify as cash flow hedges is reported as a component of AOCI. Beginning in the period in which the planned debt refinancing occurs and the related derivative instrument is terminated, the effective portion of the gains or losses is then reclassified into interest expense over the term of the related debt. At September 30, 2015 we had interest rate swaps with notional amounts totaling $ 875 designated as forward starting interest rate swaps in anticipation of future debt issuances. The market value of outstanding interest rate swap agreements at September 30, 2015 was $ 8 , which is recorded in accrued expenses and other liabilities with an offsetting amount recorded in AOCI. During the 2015 three months we terminated a forward starting interest rate swap and recorded $ 10 in AOCI related to hedges on future debt issuances. The cash flow effect of this hedge is recorded in cash flow from operations. Upon the probable issuance of the debt, these amounts will be released to interest expense over the term of the debt. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are used to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. At September 30, 2015 we had interest rate swaps in gross notional amounts of $500 designated as fair value hedges of underlying fixed rate obligations representing a portion of our $600 senior unsecured notes due in 2024. There was no hedge ineffectiveness recorded as a result of these fair value hedges. Certain amounts related to our fair value hedge instruments are: September 2015 December 2014 Gross Notional Amount $ 500 $ 500 Fair Value Other Noncurrent Assets 23 10 Long Term Debt (23 ) (10 ) $ — $ — We are exposed to credit loss in the event of nonperformance by counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS In January 2015 we completed the acquisition of certain assets of CHG Hospital Beds, Inc. (CHG). CHG designs, manufactures and markets a series of low-height hospital beds and related accessories. This acquisition is recorded within our Medsurg segment. In addition to CHG, certain other acquisitions completed in 2015 are included in the "Other" column. In 2014 we completed the acquisition of certain assets of Small Bone Innovations, Inc. (SBi) for an aggregate purchase price of approximately $ 365 , the acquisition of Berchtold Holding, AG (Berchtold) for an aggregate purchase price of approximately $ 184 and the acquisition of Patient Safety Technologies, Inc. (PST) for an aggregate purchase price of $120 . The acquired net assets of other business acquisitions completed in 2014 are in the "Other" column in the table below. The allocation of the purchase prices of each acquisition to the acquired net assets is as follows: 2015 2014 Other SBi Berchtold PST Other Purchase price paid $ 125 $ 365 $ 184 $ 120 $ 216 Contingent consideration 9 — — — — Total purchase consideration $ 134 $ 365 $ 184 $ 120 $ 216 Tangible assets: Cash — — 12 — — Inventory 9 23 22 7 5 Other assets 17 6 44 19 25 Liabilities (5 ) (2 ) (45 ) (31 ) (29 ) Intangible assets: Customer relationship 10 20 11 33 5 Trade name 1 — 7 — — Developed technology & patents 41 73 32 26 115 Non-compete agreements 2 1 — — — IPRD — 1 — — 2 Goodwill 59 243 101 66 93 $ 134 $ 365 $ 184 $ 120 $ 216 Weighted-average life of intangible assets 10 12 8 14 12 The measurement periods for SBi, Berchtold, PST and certain other acquisitions in 2014 have been completed. Revisions to the original purchase price allocation were not material. The purchase price allocations for CHG and certain other acquisitions are based upon preliminary valuations, and our estimates and assumptions are subject to change within the measurement period as the valuations are finalized. We are in the process of verifying data and information related to these acquisitions to finalize the recording of identifiable intangible assets, deferred income taxes and goodwill. Goodwill acquired associated with the SBi and CHG acquisitions are deductible for tax purposes. The effects of all the acquisitions described above are included in our Consolidated Financial Statements prospectively from the close of the respective acquisition. Pro forma consolidated results of operations for the three or nine months 2015 and 2014 would not differ significantly as a result of these acquisitions. The estimated amortization expense for our amortizable intangible assets for the next five years is: Remainder of 2015 2016 2017 2018 2019 Amortization expense $ 51 $ 172 $ 170 $ 154 $ 138

Contingencies and Commitments

Contingencies and Commitments	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Commitments	CONTINGENCIES AND COMMITMENTS We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters that are more fully described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management has sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are currently self-insured for product liability-related claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. On November 3, 2014 we announced that we had entered into a settlement agreement to compensate eligible United States patients who had revision surgery to replace their Rejuvenate and/or ABG II Modular-Neck hip stem prior to that date. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, some lawsuits will remain and we will continue to defend against them. Based on the information that has been received, the actuarially determined range of probable loss to resolve this matter on a global basis is estimated to be approximately $ 2,027 ($ 2,206 before $ 179 of third-party insurance recoveries) to $ 2,554 . In the 2015 three months, we recorded additional charges to earnings of $ 149 , representing the excess of the minimum of the range over the previously recorded reserves. In the 2015 three months we made initial payments totaling $ 1,133 to eligible United States patients who had revision surgery to replace their Rejuvenate and/or ABG II Modular-Neck hip stem as part of the settlement agreement. The final outcome of this matter is dependent on many factors that are difficult to predict including the number of enrollees in the settlement program and the total awards to them, the number and costs of patients not eligible for the settlement program who seek testing and treatment services and require revision surgery and the number and actual costs to resolve the remaining lawsuits. Accordingly, the ultimate cost to resolve this entire matter globally may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on our financial position, results of operations and cash flows. In 2010 we filed a lawsuit in federal court against Zimmer Holdings, Inc. (Zimmer), alleging that a Zimmer product infringed three of our patents. In 2013 following a jury trial favorable to us, the trial judge entered a final judgment that, among other things, awarded us damages of $ 76 and ordered Zimmer to pay us enhanced damages. Zimmer appealed this ruling. In December 2014 the Federal Circuit affirmed the damages awarded to us, reversed the order for enhanced damages and remanded the issue of attorney fees to the trial court. The Federal Circuit denied our petition for a rehearing en banc on the issue of enhanced damages but on October 19, 2015 the United States Supreme Court agreed to hear our appeal on this issue. In May 2015 the trial court entered a stipulated final judgment that, among other things, required Zimmer to pay us the base amount of damages and interest by July 15, 2015, while the issues of enhanced damages and attorney fees continue to be pursued. We concluded that all of the contingencies associated with this payment were resolved when the judgment was entered. Accordingly, we recorded a gain of $ 54 , net of legal costs, to selling, general and administrative expenses in June 2015. On July 15, 2015 we received the payment from Zimmer. In April 2011 Hill-Rom Company, Inc. and affiliated entities (Hill-Rom) brought a lawsuit against us alleging infringement under United States patent laws with respect to nine patents related to electrical network communications for hospital beds. On March 31, 2015 the court granted the parties’ joint motion to dismiss with prejudice the claims and counterclaims associated with three of these patents. The case has been stayed with respect to the remaining six patents, which currently are under reexamination by the United States Patent Office. The ultimate resolution of this matter cannot be predicted and it is not possible at this time for us to estimate any probable loss or range of probable losses. However, the ultimate result could have a material adverse effect on our financial position, results of operations and cash flows.

Debt and Credit Facilities

Debt and Credit Facilities	9 Months Ended
	Sep. 30, 2015
Long-term Debt, Unclassified [Abstract]
Debt And Credit Facilities	DEBT AND CREDIT FACILITIES During the 2015 nine months, we repaid all $ 500 of our senior unsecured notes that were due on January 15, 2015. Our commercial paper program allows us to have a maximum of $ 1,250 in commercial paper outstanding, with maturities up to 397 days from the date of issuance. At September 30, 2015 outstanding commercial paper totaled $ 200 , the weighted-average original maturity of the commercial paper outstanding was approximately 45 days and the weighted average annualized interest rate of short-term debt was approximately 1.2% . Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants at September 30, 2015 . We have lines of credit, issued by various financial institutions, available to fund our day-to-day operating needs. At September 30, 2015 we had $ 1,250 of borrowing capacity available under all of our existing credit facilities. At September 30, 2015 the total unamortized debt issuance costs incurred in connection with our outstanding notes were $ 18 . The fair value of long-term debt (excluding the interest rate hedges) at September 30, 2015 and December 31, 2014 was $ 3,284 and $ 3,811 , respectively, based on the quoted interest rates for similar types and amounts of borrowings.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2015
Class of Stock Disclosures [Abstract]
Capital Stock	CAPITAL STOCK In February 2015 we declared a quarterly dividend of $ 0.345 per share, payable on April 30, 2015 to shareholders of record at the close of business on March 31, 2015. In April 2015 we declared a quarterly dividend of $ 0.345 per share, payable on July 31, 2015 to shareholders of record at the close of business on September 30, 2015 . In July 2015 we declared a quarterly dividend of $ 0.345 per share, payable on October 30, 2015 to shareholders of record at the close of business on September 30, 2015 . In March 2015 we announced that our Board of Directors had authorized us to purchase up to $2,000 of our common stock (the 2015 Repurchase Program). In 2012, we announced that our Board of Directors had authorized us to purchase up to $405 of our common stock (the 2012 Repurchase Program). The manner, timing and amount of purchases is determined by management based on an evaluation of market conditions, stock price and other factors and is subject to regulatory considerations. Purchases are to be made from time to time in the open market, in privately negotiated transactions or otherwise. During the 2015 three months we repurchased 1.2 million shares at a cost of $ 123 under the 2012 Repurchase Program. At September 30, 2015 the maximum dollar value of shares that may yet be purchased was $ 136 under the 2012 Repurchase Program and $ 2,000 under the 2015 Repurchase Program.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Our effective tax rates for the 2015 and 2014 three months were 12.8 % and 86.6 %, respectively, and 18.3 % and 63.5 % for the 2015 and 2014 nine months, respectively. The establishment of our European regional headquarters and certain discrete tax matters impacted our effective tax rate for the 2014 three and nine months. The operating impact of our European regional headquarters and certain discrete tax matters are included in our effective tax rate for the 2015 three and nine months.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION Net sales and net earnings by business segment were: Three Months Nine Months 2015 2014 2015 2014 Orthopaedics $ 1,019 $ 1,016 $ 3,077 $ 3,043 MedSurg 943 936 2,809 2,727 Neurotechnology and Spine 458 437 1,345 1,287 Net sales $ 2,420 $ 2,389 $ 7,231 $ 7,057 Orthopaedics 288 247 827 752 MedSurg 155 158 457 443 Neurotechnology and Spine 85 100 267 260 Segment net earnings $ 528 $ 505 $ 1,551 $ 1,455 Less: other (net of income taxes) Corporate and other (52 ) (66 ) (193 ) (197 ) Acquisition and integration-related charges (1 ) (17 ) (22 ) (47 ) Amortization of intangible assets (38 ) (34 ) (107 ) (99 ) Restructuring and related charges (15 ) (8 ) (58 ) (37 ) Recall charges (127 ) (23 ) (222 ) (512 ) Legal Matters — — 46 — Tax matters 6 (300 ) (78 ) (308 ) Net earnings $ 301 $ 57 $ 917 $ 255 Other than assets associated with the acquisitions that are discussed in greater detail in Note 4, there were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2014 .

Basis Of Presentation (Policies

Basis Of Presentation (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements Not Yet Adopted	In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This guidance outlines a single, comprehensive model for accounting for revenue from contracts with customers. We will adopt the standard on January 1, 2018. We are still evaluating the impact, if any, that the standard will have on our financial statements. In April 2015 the FASB issued ASU 2015-03, Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. This update requires an entity to present debt issuance costs related to a recognized debt liability as a direct deduction from the carrying amount of that debt liability consistent with debt discounts and is effective for financial statements issued for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. We plan to adopt this standard on January 1, 2016 and do not expect it to have a material impact on the Consolidated Financial Statements. No other new accounting pronouncements issued or effective during the period had, or are expected to have, a material impact on the Consolidated Financial Statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Our valuation of our assets and liabilities measured at fair value is: September December 2015 2014 Cash and cash equivalents $ 3,163 $ 1,795 Trading marketable securities 77 80 Level 1 - Assets $ 3,240 $ 1,875 Available-for-sale marketable securities Corporate and asset-backed debt securities 68 1,525 Foreign government debt securities 80 726 United States agency debt securities 24 382 United States treasury debt securities 34 474 Certificates of deposit 5 110 Other — 12 Total available-for-sale marketable securities 211 3,229 Foreign currency exchange forward contracts 34 32 Interest rate swap asset 23 10 Level 2 - Assets 268 3,271 Total assets measured at fair value $ 3,508 $ 5,146 Deferred compensation arrangements 77 80 Level 1 - Liabilities 77 80 Foreign currency exchange forward contracts 13 12 Interest rate swap liability 8 — Level 2 - Liabilities 21 12 Contingent consideration Beginning Balance 48 59 Additions 9 — Losses included in earnings — 4 Settlements (4 ) (15 ) Balance at the end of the period 53 48 Level 3 - Liabilities 53 48 Total liabilities measured at fair value $ 151 $ 140
Available-for-sale Securities	s: September December 2015 2014 Cash and cash equivalents $ 3,163 $ 1,795 Trading marketable securities 77 80 Level 1 - Assets $ 3,240 $ 1,875 Available-for-sale marketable securities Corporate and asset-backed debt securities 68 1,525 Foreign government debt securities 80 726 United States agency debt securities 24 382 United States treasury debt securities 34 474 Certificates of deposit 5 110 Other — 12 Total available-for-sale marketable securities 211 3,229 Foreign currency exchange forward contracts 34 32 Interest rate swap asset 23 10 Level 2 - Assets 268 3,271 Total assets measured at fair value $ 3,508 $ 5,146 Deferred compensation arrangements 77 80 Level 1 - Liabilities 77 80 Foreign currency exchange forward contracts 13 12 Interest rate swap liability 8 — Level 2 - Liabilities 21 12 Contingent consideration Beginning Balance 48 59 Additions 9 — Losses included in earnings — 4 Settlements (4 ) (15 ) Balance at the end of the period 53 48 Level 3 - Liabilities 53 48 Total liabilities measured at fair value $ 151 $ 140 The cost and estimated fair value of available-for-sale marketable securities at September 30, 2015 by contractual maturity are: Cost Estimated Due in one year or less $ 90 $ 90 Due after one year through three years 118 118 Due after three years 3 3
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	Summary of marketable securities: September December 2015 2014 Available for Sale Securities: Amortized Cost Corporate and asset-backed debt securities $ 68 $ 1,523 Foreign government debt securities 80 725 United States agency debt securities 24 382 United States treasury debt securities 34 474 Certificates of deposit 5 110 Other — 12 Gross Unrealized Gains Corporate and asset-backed debt securities $ — $ 3 Foreign government debt securities — 2 Gross Unrealized Losses Corporate and asset-backed debt securities $ — $ (1 ) Foreign government debt securities — (1 ) Estimated Fair Value Corporate and asset-backed debt securities $ 68 $ 1,525 Foreign government debt securities 80 726 United States agency debt securities 24 382 United States treasury debt securities 34 474 Certificates of deposit 5 110 Other — 12 Total available-for-sale marketable securities $ 211 $ 3,229 Trading marketable securities 77 80 Total marketable securities $ 288 $ 3,309 Reported as: Current assets - marketable securities $ 209 $ 3,205 Current assets - prepaid expenses and other 2 24 Noncurrent assets - other 77 80
Investments Classified by Contractual Maturity Date	At September 30, 2015 the fair value and gross unrealized losses of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, are: Number of Investments Fair Value Unrealized Losses Corporate and asset-backed 25 $ 21 $ — Foreign Government 4 10 — United States Agency 1 5 — United States Debt 1 — — Certificate of deposit 1 1 — Less than 12 months 32 $ 37 $ — Corporate and asset-backed 26 $ 22 $ — Foreign Government 4 10 — United States Agency 1 5 — United States Debt 1 — — Certificate of Deposit 1 1 — Total 33 $ 38 $ —

Accumulated Other Comprehensi21

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in AOCI for the three months: Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning $ — $ (126 ) $ 24 $ (329 ) $ (431 ) OCI before reclassifications (1 ) (2 ) (14 ) (83 ) (100 ) Tax (benefit) expense on OCI — — 4 — 4 Reclassifications out of AOCI 1 2 (5 ) — (2 ) Net current period OCI — — (15 ) (83 ) (98 ) Ending $ — $ (126 ) $ 9 $ (412 ) $ (529 ) Changes in AOCI for the nine months: Marketable Securities Pension Plans Hedges Financial Statement Translation Total Beginning 3 (136 ) 13 (134 ) (254 ) OCI before reclassifications 2 8 6 (278 ) (262 ) Tax (benefit) expense on OCI (1 ) (2 ) (2 ) — (5 ) Reclassifications out of AOCI (4 ) 4 (8 ) — (8 ) Net current period OCI (3 ) 10 (4 ) (278 ) (275 ) Ending — (126 ) 9 (412 ) (529 )
Reclassification out of Accumulated Other Comprehensive Income	Reclassifications out of AOCI for the three and nine months: Three Months Nine Months 2015 2014 2015 2014 Marketable Securities Other (income) expense $ 1 $ (4 ) $ (5 ) $ (7 ) Tax expense (benefit) — 1 1 1 Net of tax 1 (3 ) (4 ) (6 ) Pension Plans Cost of Sales 2 — 6 — Tax expense (benefit) — — (2 ) (1 ) Net of tax 2 — 4 (1 ) Hedges Cost of Sales (7 ) — (12 ) (4 ) Tax expense (benefit) 2 — 4 2 Net of tax (5 ) — (8 ) (2 ) Total, net of tax $ (2 ) $ (3 ) $ (8 ) $ (9 )

Derivative Instruments (Tables)

Derivative Instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The gross notional, maximum term and gross fair value amounts of foreign exchange forward contract derivatives designated and non-designated as hedging instruments are: Designated Non-Designated Total September 30, 2015 Gross Notional Amount $ 565 $ 2,366 $ 2,931 Maximum term in days 546 Fair Value Other Current Assets $ 26 $ 6 $ 32 Other Noncurrent Assets 2 — 2 Other Current Liabilities (6 ) (6 ) (12 ) Other Noncurrent Liabilities (1 ) — (1 ) $ 21 $ — $ 21 December 31, 2014 Gross Notional Amount $ 357 $ 2,085 $ 2,442 Maximum term in days 546 Fair Value Other Current Assets $ 18 $ 12 $ 30 Other Noncurrent Assets 2 — 2 Other Current Liabilities — (12 ) (12 ) $ 20 $ — $ 20
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	The net currency exchange rate gains (losses) for both designated and non-designated derivative instruments and the underlying amounts are: Three Months Nine Months Recorded In: 2015 2014 2015 2014 Cost of goods sold $ 7 $ (1 ) $ 12 $ 4 Other income (expense) (5 ) (2 ) (16 ) (11 ) Total $ 2 $ (3 ) $ (4 ) $ (7 )

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The allocation of the purchase prices of each acquisition to the acquired net assets is as follows: 2015 2014 Other SBi Berchtold PST Other Purchase price paid $ 125 $ 365 $ 184 $ 120 $ 216 Contingent consideration 9 — — — — Total purchase consideration $ 134 $ 365 $ 184 $ 120 $ 216 Tangible assets: Cash — — 12 — — Inventory 9 23 22 7 5 Other assets 17 6 44 19 25 Liabilities (5 ) (2 ) (45 ) (31 ) (29 ) Intangible assets: Customer relationship 10 20 11 33 5 Trade name 1 — 7 — — Developed technology & patents 41 73 32 26 115 Non-compete agreements 2 1 — — — IPRD — 1 — — 2 Goodwill 59 243 101 66 93 $ 134 $ 365 $ 184 $ 120 $ 216 Weighted-average life of intangible assets 10 12 8 14 12
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated amortization expense for our amortizable intangible assets for the next five years is: Remainder of 2015 2016 2017 2018 2019 Amortization expense $ 51 $ 172 $ 170 $ 154 $ 138

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Sales and Other Financial Information by Business Segment	Net sales and net earnings by business segment were: Three Months Nine Months 2015 2014 2015 2014 Orthopaedics $ 1,019 $ 1,016 $ 3,077 $ 3,043 MedSurg 943 936 2,809 2,727 Neurotechnology and Spine 458 437 1,345 1,287 Net sales $ 2,420 $ 2,389 $ 7,231 $ 7,057 Orthopaedics 288 247 827 752 MedSurg 155 158 457 443 Neurotechnology and Spine 85 100 267 260 Segment net earnings $ 528 $ 505 $ 1,551 $ 1,455 Less: other (net of income taxes) Corporate and other (52 ) (66 ) (193 ) (197 ) Acquisition and integration-related charges (1 ) (17 ) (22 ) (47 ) Amortization of intangible assets (38 ) (34 ) (107 ) (99 ) Restructuring and related charges (15 ) (8 ) (58 ) (37 ) Recall charges (127 ) (23 ) (222 ) (512 ) Legal Matters — — 46 — Tax matters 6 (300 ) (78 ) (308 ) Net earnings $ 301 $ 57 $ 917 $ 255

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Marketable Securities, Gain (Loss)	$ 1	$ 10	$ 12	$ 21
Asset-backed Securities | Moody's, A Rating
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2			1.00%
Fitch, A Rating | Asset-backed Securities
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2			1.00%
Standard & Poor's, A Rating | Asset-backed Securities
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2			1.00%

Fair Value Measurements (Valuat

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2015	Dec. 31, 2014
ASSETS
Available-for-sale Securities, Current			$ 209	$ 3,205
Investments Fair Value Disclosure			3,508	5,146
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Beginning Balance	$ 140
Balance at the end of the period	151	$ 140
Total liabilities measured at fair value	140	140	151	140
Interest rate swap liability
ASSETS
Derivative Asset			0	0
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents			3,163	1,795
ASSETS
Investments Fair Value Disclosure			3,240	1,875
Fair Value Liabilities Measured On Recurring Basis Deferred Compensation Plan Liabilities			77	80
Liabilities
Liabilities, Fair Value Disclosure, Recurring			77	80
Fair Value, Inputs, Level 1 [Member] | Foreign Exchange Contract
ASSETS
Derivative Asset			34	32
Liabilities
Foreign currency exchange forward contracts			13	12
Fair Value, Inputs, Level 1 [Member] | Interest rate swap liability
ASSETS
Derivative Asset			23	10
Fair Value, Inputs, Level 1 [Member] | Trading Securities
Trading marketable securities			77	80
Fair Value, Inputs, Level 1 [Member] | Available-for-sale Securities
ASSETS
Available-for-sale Securities, Current			211	3,229
Fair Value, Inputs, Level 1 [Member] | Available-for-sale Securities | Asset-backed Securities
ASSETS
Available-for-sale Securities, Current			68	1,525
Fair Value, Inputs, Level 1 [Member] | Available-for-sale Securities | Foreign Government Debt Securities
ASSETS
Available-for-sale Securities, Current			80	726
Fair Value, Inputs, Level 1 [Member] | Available-for-sale Securities | US Government Agencies Debt Securities
ASSETS
Available-for-sale Securities, Current			24	382
Fair Value, Inputs, Level 1 [Member] | Available-for-sale Securities | United States Debt
ASSETS
Available-for-sale Securities, Current			34	474
Fair Value, Inputs, Level 1 [Member] | Available-for-sale Securities | Certificate of deposit
ASSETS
Available-for-sale Securities, Current			5	110
Fair Value, Inputs, Level 1 [Member] | Available-for-sale Securities | Other Security Investments
ASSETS
Available-for-sale Securities, Current			0	12
Fair Value, Inputs, Level 2
ASSETS
Investments Fair Value Disclosure			268	3,271
Liabilities
Liabilities, Fair Value Disclosure, Recurring			21	12
Fair Value, Inputs, Level 3
Liabilities
Liabilities, Fair Value Disclosure, Recurring			53	48
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]
Beginning Balance	48	59
Additions	9	0
Losses included in earnings		4
Settlements	(4)	(15)
Balance at the end of the period	53	48
Total liabilities measured at fair value	$ 48	$ 59	$ 53	$ 48

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities Measured At Fair Value On A Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cost due after three years	$ 90
Cost due after one year through three years	118
Cost due after three years	3
Estimated fair value due in one year or less	90
Estimated fair value due after one year through three years	118
Estimated fair value due after three years	3
Interest rate swap liability | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 8	$ 0

Fair Value Measurements (Market

Fair Value Measurements (Marketable Securities) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	$ 288	$ 3,309
Available-for-sale Securities
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	209	3,205
Current Assets, Prepaid Expenses, And Other Current Assets
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	2	24
Other Assets
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	77	80
Available-for-sale Securities
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	211	3,229
Available-for-sale Securities | Asset-backed Securities
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Available-for-sale Securities, Amortized Cost Basis	68	1,523
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	(1)
Estimated Fair Value	68	1,525
Available-for-sale Securities | Foreign Government Debt Securities
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Available-for-sale Securities, Amortized Cost Basis	80	725
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0	2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	0	(1)
Estimated Fair Value	80	726
Available-for-sale Securities | US Government Agencies Debt Securities
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Available-for-sale Securities, Amortized Cost Basis	24	382
Estimated Fair Value	24	382
Available-for-sale Securities | United States Debt
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Available-for-sale Securities, Amortized Cost Basis	34	474
Estimated Fair Value	34	474
Available-for-sale Securities | Certificate of deposit
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Available-for-sale Securities, Amortized Cost Basis	5	110
Estimated Fair Value	5	110
Available-for-sale Securities | Other Security Investments
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Available-for-sale Securities, Amortized Cost Basis	0	12
Estimated Fair Value	0	12
Trading Securities
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Estimated Fair Value	$ 77	$ 80

Fair Value Measurements (Unreal

Fair Value Measurements (Unrealized Losses And Fair Value Of Investments With Unrealized Losses) (Details) $ in Millions	Sep. 30, 2015USD ($)investment
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year | investment	32
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 37
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | investment	33
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 38
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ 0
Asset-backed Securities
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year | investment	25
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 21
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | investment	26
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 22
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ 0
Foreign Government Debt Securities
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year | investment	4
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 10
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | investment	4
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 10
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ 0
US Government Agencies Debt Securities
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year | investment	1
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 5
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | investment	1
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 5
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ 0
United States Debt
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year | investment	1
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 0
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | investment	1
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 0
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ 0
Certificate of deposit
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year | investment	1
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 1
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | investment	1
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 1
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ 0

Accumulated Other Comprehensi30

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	$ (431)		$ (254)
Other comprehensive income (OCI)	(100)		(262)
Other Comprehensive Income (Loss), Before Reclassifications, Tax	4		(5)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	(2)		(8)
Other comprehensive loss	(98)	$ (305)	(275)	$ (306)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(529)		(529)
Other income (expense), net	33	25	90	79
Cost of sales	(796)	(829)	(2,449)	(2,420)
Income taxes	44	368	206	444
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(2)	(3)	(8)	(9)
Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	0		3
Other comprehensive income (OCI)	(1)		2
Other Comprehensive Income (Loss), Before Reclassifications, Tax	0		(1)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	0		0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	1	(3)	(4)	(6)
Accumulated Defined Benefit Plans Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(126)		(136)
Other comprehensive income (OCI)	(2)		8
Other Comprehensive Income (Loss), Before Reclassifications, Tax	0		(2)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(126)		(126)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	2	0	4	(1)
Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	24		13
Other comprehensive income (OCI)	(14)		6
Other Comprehensive Income (Loss), Before Reclassifications, Tax	4		(2)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	9		9
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(5)	0	(8)	(2)
Financial Statement Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(329)		(134)
Other comprehensive income (OCI)	(83)		(278)
Other Comprehensive Income (Loss), Before Reclassifications, Tax	0		0
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(412)		(412)
Reclassification out of Accumulated Other Comprehensive Income | Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	1		(4)
Other comprehensive loss	0		(3)
Income taxes	0	1	1	1
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Defined Benefit Plans Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	2		4
Other comprehensive loss	0		10
Income taxes	0	0	(2)	(1)
Reclassification out of Accumulated Other Comprehensive Income | Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	(5)		(8)
Other comprehensive loss	(15)		(4)
Income taxes	2	0	4	2
Reclassification out of Accumulated Other Comprehensive Income | Financial Statement Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	0		0
Other comprehensive loss	(83)		(278)
Reclassification out of Accumulated Other Comprehensive Income | Other Income (expense) | Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Other income (expense), net	1	(4)	(5)	(7)
Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales | Accumulated Defined Benefit Plans Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	(2)	0	(6)	0
Reclassification out of Accumulated Other Comprehensive Income | Cost of Sales | Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales	$ (7)	$ 0	$ (12)	$ (4)

Derivative Instruments (Narrati

Derivative Instruments (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Gain (loss) on termination of derivative	$ (15,000,000)	$ 5,000,000	$ (4,000,000)	$ (7,000,000)
Foreign Exchange Contract
Notional Amount	2,931,000,000		2,931,000,000		$ 2,442,000,000
Foreign Exchange Contract | Designated as Hedging Instrument
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months			24,000,000
Notional Amount	565,000,000		565,000,000		357,000,000
Net Investment Hedging
Derivative Instruments in Hedges, Net Investment in Foreign Operations, Assets, Fair Value	8,000,000		8,000,000
Senior Unsecured Notes 3.375% due 2024
Senior Unsecured Notes			600,000,000
Other Noncurrent Liabilities | Interest rate swap liability
Interest Rate Cash Flow Hedge Liability at Fair Value	8,000,000		8,000,000
Fair Value Hedging | Net Investment Hedging | Designated as Hedging Instrument
Notional Amount	754,000,000		754,000,000
Fair Value Hedging | Interest rate swap liability | Designated as Hedging Instrument
Notional Amount	500,000,000		500,000,000		$ 500,000,000
Cash Flow Hedging | Interest rate swap liability
Gain (loss) on termination of derivative	10
Cash Flow Hedging | Interest rate swap liability | Designated as Hedging Instrument
Notional Amount	$ 875,000,000		$ 875,000,000

Derivative Instruments (Forward

Derivative Instruments (Forward Currency Exchange Contracts) (Details) - Foreign Exchange Contract - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Derivative [Line Items]
Notional Amount	$ 2,931	$ 2,442
Maximum Term (Days)	546 days	546 days
Derivative, Fair Value, Net	$ 21	$ 20
Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	565	357
Derivative, Fair Value, Net	21	20
Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	2,366	2,085
Derivative, Fair Value, Net	0	0
Other Current Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	32	30
Other Current Assets | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	26	18
Other Current Assets | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	6	12
Other Noncurrent Assets
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	2	2
Other Noncurrent Assets | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	2	2
Other Noncurrent Assets | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Asset, Fair Value, Gross Asset	0	0
Other Current Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	(12)	(12)
Other Current Liabilities | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	(6)	0
Other Current Liabilities | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	(6)	$ (12)
Other Noncurrent Liabilities
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	(1)
Other Noncurrent Liabilities | Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	(1)
Other Noncurrent Liabilities | Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liability, Fair Value, Gross Liability	$ 0

Derivative Instruments (Income

Derivative Instruments (Income Statement Location) (Details) - Foreign Exchange Contract - USD ($) $ in Millions	3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax			$ (4)	$ (7)
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ 2	$ (3)
Cost of Sales
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax			12	4
Cost of Sales | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	7	(1)
Other Income (expense)
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax			$ (16)	$ (11)
Other Income (expense) | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ (5)	$ (2)

Derivative Instruments Derivati

Derivative Instruments Derivative Instrument - Designated Interest Rate Hedge (Details) - Interest rate swap liability - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset	$ 0	$ 0
Designated as Hedging Instrument | Fair Value Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	500	500
Other Noncurrent Assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Fair Value, Gross Asset	23	10
Long-term Debt
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Fair Value, Gross Liability	$ (23)	$ (10)

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Millions	Dec. 31, 2014USD ($)
Small Bone Innovations
Business Acquisition [Line Items]
Intangible assets	$ 365
Berchtold
Business Acquisition [Line Items]
Intangible assets	184
PST
Business Acquisition [Line Items]
Intangible assets	$ 120

Acquisitions (Allocation Of The

Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of The Trauson Acquisition (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Goodwill	$ 4,160	$ 4,186
Other
Purchase price paid	125	216
Contingent consideration	9	0
Total purchase consideration	134	216
Cash	0	0
Inventory	9	5
Other assets	17	25
Liabilities	(5)	(29)
Goodwill	59	93
Assets and liabilities acquired, net	$ 134	$ 216
Tangible assets acquired:	10 years	12 years
Other | Customer relationship
Intangible assets:	$ 10	$ 5
Other | Trade name
Intangible assets:	1	0
Other | Developed technology & patents
Intangible assets:	41	115
Other | Noncompete Agreements
Intangible assets:	2	0
Other | IPRD
Intangible assets:	$ 0	2
Small Bone Innovations
Purchase price paid		365
Contingent consideration		0
Total purchase consideration		365
Cash		0
Inventory		23
Other assets		6
Liabilities		(2)
Goodwill		243
Assets and liabilities acquired, net		$ 365
Tangible assets acquired:		12 years
Small Bone Innovations | Customer relationship
Intangible assets:		$ 20
Small Bone Innovations | Trade name
Intangible assets:		0
Small Bone Innovations | Developed technology & patents
Intangible assets:		73
Small Bone Innovations | IPRD
Intangible assets:		1
Berchtold
Purchase price paid		184
Contingent consideration		0
Total purchase consideration		184
Cash		12
Inventory		22
Other assets		44
Liabilities		(45)
Goodwill		101
Assets and liabilities acquired, net		$ 184
Tangible assets acquired:		8 years
Berchtold | Customer relationship
Intangible assets:		$ 11
Berchtold | Trade name
Intangible assets:		7
Berchtold | Developed technology & patents
Intangible assets:		32
Berchtold | Noncompete Agreements
Intangible assets:		0
Berchtold | IPRD
Intangible assets:		0
PST
Purchase price paid		120
Contingent consideration		0
Total purchase consideration		120
Cash		0
Inventory		7
Other assets		19
Liabilities		(31)
Goodwill		66
Assets and liabilities acquired, net		$ 120
Tangible assets acquired:		14 years
PST | Customer relationship
Intangible assets:		$ 33
PST | Trade name
Intangible assets:		0
PST | Developed technology & patents
Intangible assets:		26
PST | Noncompete Agreements
Intangible assets:		0
PST | IPRD
Intangible assets:		$ 0

Acquisitions - Future Amortizat

Acquisitions - Future Amortization Expense (Details) $ in Millions	Sep. 30, 2015USD ($)
Business Combinations [Abstract]
Remainder of 2015	$ 51
2,016	172
2,017	170
2,018	154
2,019	$ 138

Contingencies and Commitments (

Contingencies and Commitments (Narrative) (Details) $ in Millions	1 Months Ended		3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2015USD ($)	Apr. 30, 2011patent	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2010patent
Rejuvenate and ABG II Voluntary Recall
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss			$ 2,206	$ 2,206
Insurance Recoveries				179
Estimated Litigation Liability			149	149
Loss Contingency, Damages Awarded, Value			1,133
Rejuvenate and ABG II Voluntary Recall | Minimum
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss			2,027	2,027
Rejuvenate and ABG II Voluntary Recall | Maximum
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss			$ 2,554	$ 2,554
Zimmer Product Infringement
Loss Contingencies [Line Items]
Gain Contingency, Patents Allegedly Infringed upon, Number | patent						3
Loss Contingency, Damages Awarded, Value					$ 76
Proceeds from Legal Settlements	$ 54
Hill-Rom Company
Loss Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number | patent		9
Loss Contingency, Patents Found Not Infringed, Number | patent		3
Loss Contingency, Patents Found Infringed, Number | patent		6

Debt and Credit Facilities (Nar

Debt and Credit Facilities (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument, Maturity	397 days
Commercial Paper, at Carrying Value	$ 200
Short-term Debt, Weighted Average Interest Rate	1.20%
Line of Credit Facility, Remaining Borrowing Capacity	$ 1,250
Unamortized Debt Issuance Expense	18
Debt Instrument, Fair Value Disclosure	3,284	$ 3,811
3.00% senior unsecured notes, due January 15, 2015
Repayments of Unsecured Debt	$ 500
Commercial paper
Debt Instrument, Maturity	45
Commercial paper | Maximum
Commercial paper	$ 1,250

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2015
Cash dividends declared, per share of common stock	$ 0.345	$ 0.345	$ 0.345	$ 1.035
Stock Repurchased and Retired During Period, Shares				4.7
Repurchase and retirement of 1.3 million shares of common stock				$ 446
2015 $2.0 Billion Repurchase Agreement
Stock Repurchase Program, Authorized Amount	$ 2,000			2,000
Repurchase and retirement of 1.3 million shares of common stock	0
Stock Repurchase Program, Remaining Authorized Repurchase Amount	0			0
2012 $405.0 Million Repurchase Agreement
Stock Repurchase Program, Authorized Amount	$ 405			405
Stock Repurchased and Retired During Period, Shares	1.2
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 0			$ 0

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	12.80%	86.60%	18.30%	63.50%

Segment Information (Sales And

Segment Information (Sales And Other Financial Information By Business Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Net sales	$ 2,420	$ 2,389	$ 7,231	$ 7,057
Segment net earnings	378	450	1,213	778
Acquisition and integration-related charges	(1)	(17)	(22)	(47)
Amortization of intangible assets	(38)	(34)	(107)	(99)
Restructuring and related charges	(15)	(8)	(58)	(37)
Recall charges	(127)	(23)	(222)	(512)
Legal Matters			46
Tax matters	6	(300)	(78)	(308)
Net earnings	301	57	917	255
Operating Segments
Net sales	2,420	2,389	7,231	7,057
Segment net earnings	528	505	1,551	1,455
Operating Segments | Orthopaedics
Net sales	1,019	1,016	3,077	3,043
Segment net earnings	288	247	827	752
Operating Segments | MedSurg
Net sales	943	936	2,809	2,727
Segment net earnings	155	158	457	443
Operating Segments | Neurotechnology and Spine
Net sales	458	437	1,345	1,287
Segment net earnings	85	100	267	260
Corporate and Other
Segment net earnings	$ (52)	$ (66)	$ (193)	$ (197)